



## Molecular Partners Publishes Invitation to Annual General Meeting 2017

April 13, 2017

**Zurich-Schlieren, April 13, 2017.** Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Annual General Meeting 2017.

The Annual General Meeting will be held on Thursday, May 11, 2017, 2.00 pm CET (doors open at 1.00 pm), at the SIX Swiss Exchange Convention Point Conference Center, Room Exchange, Selnastrasse 30, 8021 Zurich.

[Link to the Invitation](#) to the Annual General Meeting 2017 with the corresponding agenda items.

[Link zur Einladung](#) zur Generalversammlung 2017 mit den zugehörigen Traktandenpunkten.

### Financial Calendar

May 4, 2017	Q1 2017 Management Statement
May 11, 2017	Annual General Meeting
August 30, 2017	Publication of 2017 Half-year Results
October 26, 2017	Q3 2017 Management Statement

<http://investors.molecularpartners.com/financial-calendar-and-events/>

### About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of therapies known as DARPin® therapies. With a management team that includes many of the founding scientists, the company continues to attract talented individuals who share the passion to develop breakthrough medicines for serious diseases. Molecular Partners has compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company establishes research and development partnerships with leading pharmaceutical companies and is backed by established biotech investors.

For more information regarding Molecular Partners AG, go to: [www.molecularpartners.com](http://www.molecularpartners.com).

### For further details please contact:

Dr. Patrick Amstutz, acting CEO  
[patrick.amstutz@molecularpartners.com](mailto:patrick.amstutz@molecularpartners.com)  
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO  
[andreas.emmenegger@molecularpartners.com](mailto:andreas.emmenegger@molecularpartners.com)  
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer  
Hirzel.Neef.Schmid.Counselors  
[rolf.schlaepfer@konsulenten.ch](mailto:rolf.schlaepfer@konsulenten.ch)  
Tel: +41 (0) 43 344 42 42

S.A. Noonan  
Susan A. Noonan Communications, LLC  
[susan@sanoonan.com](mailto:susan@sanoonan.com)  
Tel: +1 212 966 3650

### Disclaimer

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Molecular Partners AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.